首页> 外文会议>Medical laser applications and laser-tissue interactions VI >KillerRed and miniSOG as genetically encoded photosensitizers for photodynamic therapy of cancer
【24h】

KillerRed and miniSOG as genetically encoded photosensitizers for photodynamic therapy of cancer

机译:KillerRed和miniSOG作为遗传光敏剂用于癌症的光动力治疗

获取原文
获取原文并翻译 | 示例

摘要

Despite of the success of photodynamic therapy (PDT) in cancer treatment, the problems of low selective accumulation of a photosensitizer in a tumor and skin phototoxicity have not resolved yet. The idea of encoding of a photosensitizer in genome of cancer cells is attractive, particularly because it can provide highly selective light induced cell killing. This work is aimed at the development of new approach to PDT of cancer, namely to using genetically encoded photosensitizers. A phototoxicity of red fluorescent GFP-like protein KillerRed and FMN-binding protein miniSOG was investigated on HeLa tumor xenografts in nude mice. The tumors were generated by subcutaneous injection of HeLa cells stably expressing the phototoxic proteins. The tumors were irradiated with 594 run or 473 run laser at 150 mW/cm~2 for 20 or 30 min, repeatedly. Fluorescence intensity of the tumors was measured in vivo before and after each treatment procedure. Detailed pathomorphological analysis was performed 24 h after the therapy. On the epi-fluorescence images in vivo photobleaching of both proteins was observed indicating photodynamic reaction. Substantial pathomorphological abnormalities were found in the treated KillerRed-expressing tumor tissue, such as vacuolization of cytoplasm, cellular and nuclear membrane destruction, activation of apoptosis. In contrast, miniSOG-expressing tumors displayed no reaction to PDT, presumably due to the lack of FMN cofactor needed for fluorescence recovery of the flavoprotein. The results are of interest for photodynamic therapy as a proof of possibility to induce photodamages in cancer cells in vivo using genetically encoded photosensitizers.
机译:尽管光动力疗法(PDT)在癌症治疗中取得了成功,但是光敏剂在肿瘤中选择性积聚的低和皮肤光毒性的问题尚未解决。在癌细胞的基因组中编码光敏剂的想法很有吸引力,特别是因为它可以提供高度选择性的光诱导的细胞杀伤作用。这项工作旨在开发一种新的癌症PDT方法,即使用基因编码的光敏剂。研究了红色荧光GFP样蛋白KillerRed和FMN结合蛋白miniSOG对HeLa裸鼠异种移植的光毒性。通过皮下注射稳定表达光毒性蛋白的HeLa细胞产生肿瘤。用594nm或473nm激光以150mW / cm 2重复照射肿瘤20或30分钟。在每个治疗程序之前和之后在体内测量肿瘤的荧光强度。治疗后24小时进行了详细的病理形态学分析。在落射荧光图像上,观察到两种蛋白的体内光致漂白,表明光动力学反应。在治疗的表达KillerRed的肿瘤组织中发现大量病理形态异常,例如细胞质空泡化,细胞和核膜破坏,凋亡激活。相反,表达miniSOG的肿瘤对PDT无反应,大概是由于缺乏黄素蛋白荧光恢复所需的FMN辅助因子。该结果对于光动力疗法而言是令人感兴趣的,以作为使用遗传编码的光敏剂在体内诱导癌细胞光损伤的可能性的证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号